Amneal Pharmaceuticals Inc Dossier - Source-backed chat

Amneal Pharmaceuticals Inc

AMRXNASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)1.17

Intrinsic Value $14.14median of 6 methods · middle span $9-$17based on filings through 30 Jun 2026

Market Price $20.14Price as of 30 Sep 2026

OvervaluedIntrinsic value is 30% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $7B

Enterprise Value $9.5B

Shares Outstanding 330.2M diluted

Moat Rating Wide

Next Earnings Date29 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Amneal Pharmaceuticals is successfully transitioning from a traditional generics manufacturer into a high-margin, diversified biopharmaceutical leader. The company's growth is driven by its expanding Specialty portfolio (led by CREXONT for Parkinson's disease), a robust biosimilars pipeline accelerated by the transformative $750 million acquisition of Kashiv BioSciences, and strategic partnerships such as its GLP-1 development deal with Pfizer. Despite carrying a leveraged balance sheet, Amneal's strong operational execution, expanding gross margins, and upgraded 2026 guidance support a compelling investment case with significant long-term upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.00

Mean target$20.75

High · most bullish analyst$25.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$16.00

Generic erosion of Rytary occurs faster than CREXONT can scale, leading to a contraction in Specialty segment revenues. Integration challenges or regulatory delays with the Kashiv acquisition stall the biosimilars pipeline. High leverage (3.5x net debt/EBITDA) remains sticky due to weaker-than-expected operating cash flows, limiting financial flexibility and weighing on the stock's valuation.

Base CaseCentral scenario

$20.75

Matches the consensus mean

Amneal delivers on its updated standalone 2026 guidance, achieving net revenues of $3.05B-$3.15B and adjusted EBITDA of $740M-$770M. CREXONT uptake steadily offsets the expected generic erosion of Rytary, keeping the Specialty segment stable before returning to growth in 2027. The Kashiv integration proceeds as planned, positioning the company to achieve its 2030 revenue target of $4.25B-$4.5B.

Bull CaseUpside scenario

$25.00

Rapid commercial adoption of CREXONT and newly launched products like the BREKIYA autoinjector outpaces expectations. The Kashiv BioSciences acquisition closes smoothly in H2 2026, accelerating biosimilar launches and capturing a substantial share of the $300B+ global biologic loss-of-exclusivity wave. Strong cash generation drives rapid deleveraging below 3.0x ahead of the 2028 target, prompting credit rating upgrades and multiple expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transformative Kashiv BioSciences acquisition establishes a fully integrated, global biosimilars platform to capture a massive $300B+ loss-of-exclusivity market opportunity.
Strong commercial execution in the Specialty segment, highlighted by the launch of CREXONT and the BREKIYA autoinjector.
Significant margin expansion driven by a favorable product mix shift toward high-margin complex generics, biosimilars, and specialty brands.
Upgraded standalone 2026 financial guidance reflecting robust operational momentum and a clear long-term growth roadmap to 2030.

Key Investment Risks

High financial leverage with net debt of $2.49 billion and a net leverage ratio of 3.5x as of Q1 2026.
Risk of accelerated generic erosion of key legacy products, particularly Rytary in the Specialty segment.
Execution and integration risks associated with the $750 million acquisition of Kashiv BioSciences.
Regulatory hurdles or delays in obtaining FDA approvals for complex generics and biosimilars in the pipeline.

Thesis Invalidation Triggers

Failure to close or successfully integrate the Kashiv BioSciences acquisition in H2 2026.
A sharp decline in CREXONT prescription growth or unexpected safety/regulatory issues.
Inability to generate sufficient operating cash flow to meet deleveraging targets, keeping net leverage above 3.5x.
Severe pricing pressure or unexpected competitive entries in the Affordable Medicines segment.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.